PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[S]

Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases Lp(a). The potential mechanisms were assessed. A pooled analysis of Lp(a) and LDL cholesterol (LDL-C) in 3,278 patients from 10 clinical trials (eight phase 2/3; two extensions) was conducted. Within each parent study, biweekly and monthly doses of evolocumab statistically significantly reduced Lp(a) at week 12 versus control (P < 0.001 within each study); pooled median (quartile 1, quartile 3) percent reductions were 24.7% (40.0, 3.6) and 21.7% (39.9, 4.2), respectively. Reductions were maintained through week 52 of the open-label extension, and correlated with LDL-C reductions [with and without correction for Lp(a)-cholesterol] at both time points (P < 0.0001). The effect of LDL and LDL receptor (LDLR) availability on Lp(a) cell-association was measured in HepG2 cells: cell-associated LDL fluorescence was reversed by unlabeled LDL and Lp(a). Lp(a) cell-association was reduced by coincubation with LDL and PCSK9 and reversed by adding PCSK9 mAb. These studies support that reductions in Lp(a) with PCSK9 inhibition are partly due to increased LDLR-mediated uptake. In most situations, Lp(a) appears to compete poorly with LDL for LDLR binding and internalization, but when LDLR expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a) is reduced.

[1]  V. Armstrong,et al.  Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. , 1990, Journal of lipid research.

[2]  J. Kjekshus,et al.  Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study , 1997, Clinical genetics.

[3]  R Bailén Almorox,et al.  [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol]. , 2012, Revista clinica espanola.

[4]  J. Dietschy,et al.  Cholesterol metabolism in the brain , 2001, Current opinion in lipidology.

[5]  V. Armstrong,et al.  Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). , 1985, Journal of lipid research.

[6]  Randal R Ketchem,et al.  Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity–Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor–Binding Enhancement , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[7]  N. Murgolo,et al.  PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. , 2008, Biochemical and biophysical research communications.

[8]  Yan Wang,et al.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates , 2009, Proceedings of the National Academy of Sciences.

[9]  S. Wasserman,et al.  Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study , 2012, The Lancet.

[10]  H. Bays,et al.  Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.

[11]  MomiaoXiong,et al.  Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor , 2012 .

[12]  F. Raal,et al.  Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole , 2012, Circulation.

[13]  N. Seidah,et al.  Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor* , 2015, The Journal of Biological Chemistry.

[14]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[15]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[16]  A. Sposito,et al.  Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. , 2002, Atherosclerosis.

[17]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[18]  L. Becker,et al.  Scavenger receptor-BI is a receptor for lipoprotein(a) , 2013, Journal of Lipid Research.

[19]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[20]  V. Armstrong,et al.  Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[21]  A. Prat,et al.  The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2* , 2008, Journal of Biological Chemistry.

[22]  R. Giugliano,et al.  Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study , 2012, The Lancet.

[23]  P. Clopton,et al.  Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). , 2016, Journal of clinical lipidology.

[24]  A. Keech,et al.  Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. , 2016, American heart journal.

[25]  M. Weintraub,et al.  HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. , 1989, Circulation.

[26]  V. Gebski,et al.  Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. , 2012, JAMA.

[27]  D. Hunninghake,et al.  Effects of One Year of Treatment with Pravastatin, an HMG‐CoA Reductase Inhibitor, on Lipoprotein a , 1993, Journal of clinical pharmacology.

[28]  O. Mors,et al.  The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. , 2014, Cell metabolism.

[29]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[30]  Jennifer G. Robinson,et al.  Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. , 2014, JAMA.

[31]  J. Fallon,et al.  The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. , 1997, The Journal of clinical investigation.

[32]  R. Simó,et al.  Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial. , 2011, Diabetes & metabolism.

[33]  R. Giugliano,et al.  Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial , 2014, Circulation.

[34]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[35]  J. Renger,et al.  PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain , 2010, Journal of Lipid Research.

[36]  R. Giugliano,et al.  Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. , 2014, Journal of the American College of Cardiology.

[37]  Lesley Burgess,et al.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[38]  A. Prat,et al.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1) , 2013, PloS one.

[39]  J. Crouse,et al.  Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. , 1999, The American journal of cardiology.

[40]  J. Witztum,et al.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study , 2015, The Lancet.

[41]  A. Shaywitz,et al.  Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. , 2012, Journal of the American College of Cardiology.

[42]  R. Sivaraj,et al.  Effect of statins on lipoprotein (a) in dyslipidemic patients , 2014 .

[43]  J. Mckenney,et al.  Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). , 2014, The American journal of cardiology.

[44]  W. C. Breckenridge,et al.  Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). , 1986, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[45]  G. Watts,et al.  Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.